According to sources familiar with the matter, merger talks between biopharmaceutical giant Gilead Sciences and biotechnology company Ouro Medicines have entered a key stage.

Both parties are currently negotiating the final terms, and if talks proceed smoothly, this highly anticipated deal may be formally announced to the public in the coming days. This potential acquisition will strengthen Gilead's strategic position in the field of innovative therapies. Ouro Medicines specializes in developing gene editing technologies targeting genetic diseases, and its research pipeline aligns closely with Gilead's expansion strategy in rare disease treatments. Industry analysts suggest that if the deal is finalized, it could generate over 1 billion USD in value. Market observers point out that this move continues Gilead’s strategy in recent years of accelerating innovation through acquisitions. The company previously entered the cell therapy field by acquiring firms such as Kite Pharma, and this deal could further consolidate its leading position in gene therapy. As negotiations reach their final stages, both companies’ share prices have shown upward volatility in recent days.